Novartis Q3 Performance
Novartis' Q3 performance was driven by fast growth in recently label-expanded drugs, despite generic competition affecting established blockbusters.
Net sales for the company rose 7% in constant currencies to $13.9bn in Q3, in line with Wall Street forecasts. Core operating income reached $5.46bn, slightly above consensus analyst predictions of $5.4bn.
Oncology Segment Growth
Drugs from Novartis' oncology segment, such as breast cancer treatment Kisqali (ribociclib), spurred much of the growth, with a 68% increase in Q3 2025 compared to Q3 2024.
The gold standard of business intelligence.
Author's summary: Novartis' Q3 performance driven by new drugs growth.
More News
- Why Impact Investing Might Collapse and How to Stop It (SSIR)
- LOOK Keo Vision Pedals Light the Way — Keo Blade Ceramic Vision, Keo 2 Max Vision & Vision Upgrade Kit
- Novartis Q3: new drugs step up as generics squeeze Entresto - Pharmaceutical Technology
- Cameco, Brookfield involved in $80 billion U.S. nuclear reactor deal
- California wants to overhaul high school learning. This school is leading the way
- MLB: The Last 10 World Series MVPs
- United Parcel Service (UPS) Tops Q3 Earnings and Revenue Estimates
- Brookfield/Cameco-owned Westinghouse secures US nuclear construction deal
- Melissa second landfall in eastern Cuba Wednesday morning - The Weather Network
- MCU Blade Has Never Fought a Vampire and That’s Kinda Hilarious